Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (Insight Kids)
Primary Purpose
Diabetes Mellitus Type 1
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Accu-Chek Insight Pump System
Sponsored by
About this trial
This is an interventional diagnostic trial for Diabetes Mellitus Type 1
Eligibility Criteria
Inclusion Criteria:
- Children and adolescents at least 24 months of age, and not more than 17 years of age at screening
- Diagnosed with type 1 diabetes
- Diagnosis of type 1 diabetes established > 6 months before study start if >5 years of age
- Indication for insulin pump therapy according to local guidelines
- Subject's most recent HbA1c is equal or above 7.0% (53.0 mmol/mol) - measured at last assessment before screening within the past 2 months prior to the Baseline Visit into the study
- Willingness to use automated bolus advice obtained from the Accu-Chek Insight diabetes therapy system during the study
- Willingness and ability to participate and comply with study procedures
Exclusion Criteria:
- Disease or condition that in the opinion of the investigator is likely to affect compliance or the ability to complete the study
- Not willing or able to start insulin pump therapy
- Not willing to self-measure blood glucose at least four times daily
- Significantly impaired awareness of hypoglycemia
- More than one hospitalization for severe hypoglycemia during the last 12 months
- History of recurrent ketoacidosis during intensive insulin therapy
- Known strong plaster incompatibility and/or allergy
- Unstable chronic disease other than diabetes (e.g. impaired hepatic function, impaired renal function, impaired cardiac function, uncontrolled vascular complications) and any other condition interfering with the study procedures, as per Investigator´s discretion.
- If on antihypertensive, thyroid, anti-depressant or lipid-lowering medication, lack of stability on the medication for the past 2 months prior to the Baseline Visit in the study
- Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
- Prescription medications other than insulin interfering with diabetes management
- Acute illness or abnormality (e.g. impaired vision, impaired motor function, acute pain) at the time of screening interfering with study procedures, affecting compliance, or the ability to complete the study as per Investigator´s discretion
- Either pregnant or breastfeeding
- Drug dependency
- Dependency on sponsor or Investigator (e.g. co-worker or family member)
Sites / Locations
- Medical University Graz
- Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie
- Medical University of Vienna-Dept of Pediatrics
- Kinderkrankenhaus auf der Bult
- Gemeinschaftspraxis für Kinder- und Jugendmedizin
- Practice for Pediatric and Adolescent Diabetology
- Universitatsklinikum Tubingen
- Birmingham Children's Hospital Foundation Trust
- St. James's University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Continuous Subcutaneous Insulin Infusion (CSII)
Arm Description
Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
Outcomes
Primary Outcome Measures
Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%
This HbA1c target of <7.5% proportion is statistically tested against a proportion of 25%, composed of the anticipated population proportion of 15% of children and adolescents using multiple daily insulin injections plus a safety margin of 10%.
Secondary Outcome Measures
Score on Insulin Pump Questionnaire
Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Score on Pediatric Quality of Life Inventory (PedsQL)
Change from Baseline in HbA1c
Change from Baseline in Blood Glucose
Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)
Full Information
NCT ID
NCT02403375
First Posted
March 26, 2015
Last Updated
November 23, 2017
Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care GmbH
1. Study Identification
Unique Protocol Identification Number
NCT02403375
Brief Title
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
Acronym
Insight Kids
Official Title
Insight Kids Study: Reaching HbA1c Targets in Children and Adolescents With Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 17, 2015 (Actual)
Primary Completion Date
October 26, 2017 (Actual)
Study Completion Date
October 26, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care GmbH
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy. Furthermore, this study will add clinical data originating from clinical investigation in a special population, i.e. children and adolescents of ages 2 - 17 years , to the existing clinical data of the ACCU-CHEK Insight insulin pump.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 1
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Continuous Subcutaneous Insulin Infusion (CSII)
Arm Type
Experimental
Arm Description
Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
Intervention Type
Device
Intervention Name(s)
Accu-Chek Insight Pump System
Intervention Description
Continuous subcutaneous insulin infusion pump
Primary Outcome Measure Information:
Title
Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%
Description
This HbA1c target of <7.5% proportion is statistically tested against a proportion of 25%, composed of the anticipated population proportion of 15% of children and adolescents using multiple daily insulin injections plus a safety margin of 10%.
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Score on Insulin Pump Questionnaire
Time Frame
26 weeks
Title
Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time Frame
26 weeks
Title
Score on Pediatric Quality of Life Inventory (PedsQL)
Time Frame
26 weeks
Title
Change from Baseline in HbA1c
Time Frame
26 weeks
Title
Change from Baseline in Blood Glucose
Time Frame
26 weeks
Title
Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)
Time Frame
26 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children and adolescents at least 24 months of age, and not more than 17 years of age at screening
Diagnosed with type 1 diabetes
Diagnosis of type 1 diabetes established > 6 months before study start if >5 years of age
Indication for insulin pump therapy according to local guidelines
Subject's most recent HbA1c is equal or above 7.0% (53.0 mmol/mol) - measured at last assessment before screening within the past 2 months prior to the Baseline Visit into the study
Willingness to use automated bolus advice obtained from the Accu-Chek Insight diabetes therapy system during the study
Willingness and ability to participate and comply with study procedures
Exclusion Criteria:
Disease or condition that in the opinion of the investigator is likely to affect compliance or the ability to complete the study
Not willing or able to start insulin pump therapy
Not willing to self-measure blood glucose at least four times daily
Significantly impaired awareness of hypoglycemia
More than one hospitalization for severe hypoglycemia during the last 12 months
History of recurrent ketoacidosis during intensive insulin therapy
Known strong plaster incompatibility and/or allergy
Unstable chronic disease other than diabetes (e.g. impaired hepatic function, impaired renal function, impaired cardiac function, uncontrolled vascular complications) and any other condition interfering with the study procedures, as per Investigator´s discretion.
If on antihypertensive, thyroid, anti-depressant or lipid-lowering medication, lack of stability on the medication for the past 2 months prior to the Baseline Visit in the study
Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
Prescription medications other than insulin interfering with diabetes management
Acute illness or abnormality (e.g. impaired vision, impaired motor function, acute pain) at the time of screening interfering with study procedures, affecting compliance, or the ability to complete the study as per Investigator´s discretion
Either pregnant or breastfeeding
Drug dependency
Dependency on sponsor or Investigator (e.g. co-worker or family member)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cosima Rieger, Dr.
Organizational Affiliation
Roche Diabetes Care GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Medical University Graz
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Medical University of Vienna-Dept of Pediatrics
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Kinderkrankenhaus auf der Bult
City
Hannover
ZIP/Postal Code
30173
Country
Germany
Facility Name
Gemeinschaftspraxis für Kinder- und Jugendmedizin
City
Herford
ZIP/Postal Code
32051
Country
Germany
Facility Name
Practice for Pediatric and Adolescent Diabetology
City
Munster
ZIP/Postal Code
48155
Country
Germany
Facility Name
Universitatsklinikum Tubingen
City
Tubingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Birmingham Children's Hospital Foundation Trust
City
Birmingham
ZIP/Postal Code
B46NH
Country
United Kingdom
Facility Name
St. James's University Hospital
City
Leeds
ZIP/Postal Code
LS97TF
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
We'll reach out to this number within 24 hrs